Related Experiment Video
Updated: Jul 2, 2026
Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
Published on: November 17, 2023
A proposal for integrating intraductal carcinoma of the prostate into pathological T substaging
Remi Semba1, Katsunori Uchida2, Takeshi Sasaki3
1Department of Pathology, Kuwana City Medical Center, Mie, Japan.
Background:
The present study aims primarily to determine how incorporation of intraductal carcinoma of the prostate (IDCP) detected in radical prostatectomy (RP) specimens into pathological T (pT) impacts patient outcomes.
Methods:
The study included 1,190 patients who had undergone RP at Mie University Hospital (Tsu, Mie, Japan) from 2015 to 2023 (n = 470) and at the University of Rochester Medical Center (Rochester, NY, USA) from 2010 to 2011 (n = 720). The risks of biochemical recurrence (BCR) were compared in RP patients with or without IDCP according to the pT stage (i.e., pT2/IDCP+, pT2/IDCP-, pT3a/IDCP+, pT3a/IDCP-, pT3b/IDCP+, and pT3b/IDCP-).
Results:
The prognosis of the pT2/IDCP group was significantly better than that of the other groups (P < 0.001). Meanwhile, there was no statistically significant difference in BCR between pT2/IDCP+ and pT3a/IDCP- (P = 0.548). In pT3b patients, IDCP had no additional prognostic impact.
Conclusions:
IDCP in pT2 and pT3a cases was strongly associated with the risk of BCR. In addition, the prognosis for pT2/IDCP + versus pT3a/IDCP- or pT3b/IDCP- versus pT3b/IDCP+ was comparable. These findings indicate that IDCP may confer a BCR risk comparable to that of extraprostatic extension in pT2 cases but its prognostic impact appears limited in pT3b disease.
